EGFR and cancer: The HER family (including the Epidermal Growth Factor Receptor/HER1, HER2, HER3 and HER4) of tyrosine kinase receptors (RTKs) is highly prevalent within numerous cancer types (including breast, lung, colon, head and neck, among others), and, in some cases, antibody-based therapeutics (i.e. Trastuzumab) are highly effective [1].